BEAM (NASDAQ) - Beam Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US07373V1052
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for BEAM (NASDAQ) - Beam Therapeutics Inc


Market Cap in USD 1,858m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-02-06


Fundamental -4.94
Dividend -
Performance 5y -0.22
Rel. Performance vs Sector -2.13
Analysts 4.40
Fair Price Total Ret. 21.68
Fair Price DCF todo


Growth TTM -49.37%
CAGR 5y 7.06%
CAGR / Mean Drawdown 5y 0.16
Sharpe Ratio TTM -0.94
Alpha vs SP500 TTM -77.61
Beta vs SP500 5y weekly 1.43
CAPM 8.41%
Average Daily Range 2m 4.20%
Reversal Oscillator 58.53
Volatility GJR Garch 1y 43.13%
Price / SMA 50 -6.2%
Price / SMA 200 -28.04%
Current Volume 903.3k
Average Volume 20d 911.2k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%